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ABSTRACT
XRCC1 operates as a scaffold protein in base
excision repair, a pathway that copes with base
and sugar damage in DNA. Studies using recombin-
ant XRCC1 proteins revealed that: a C389Y substi-
tution, responsible for the repair defects of the
EM-C11 CHO cell line, caused protein instability; a
V86R mutation abolished the interaction with POLb,
but did not disrupt the interactions with PARP-1,
LIG3a and PCNA; and an E98K substitution,
identified in EM-C12, reduced protein integrity, mar-
ginally destabilized the POLb interaction, and
slightly enhanced DNA binding. Two rare (P161L
and Y576S) and two frequent (R194W and R399Q)
amino acid population variants had little or no
effect on XRCC1 protein stability or the interactions
with POLb, PARP-1, LIG3a, PCNA or DNA. One
common population variant (R280H) had no
pronounced effect on the interactions with POLb,
PARP-1, LIG3a and PCNA, but did reduce
DNA-binding ability. When expressed in HeLa cells,
the XRCC1 variants—excluding E98K, which was
largely nucleolar, and C389Y, which exhibited
reduced expression—exhibited normal nuclear dis-
tribution. Most of the protein variants, including the
V86R POLb-interaction mutant, displayed normal
relocalization kinetics to/from sites of laser-induced
DNA damage: except for E98K and C389Y, and the
polymorphic variant R280H, which exhibited a
slightly shorter retention time at DNA breaks.
INTRODUCTION
Once thought to be an extraordinarily stable molecule,
DNA is now recognized to be susceptible to both spon-
taneous decay and attack from a number of chemical
agents, most notably endogenous reactive oxygen species
(1). The most common forms of DNA damage, particu-
larly under normal physiological conditions (i.e. in the
absence of environmental challenges), are base modifica-
tions, abasic (AP) sites and single-strand breaks (SSBs).
If unrepaired, such genetic damage can lead to inaccurate
copying of the genome, chromosome instability, and
blockage of transcription or replication. Such outcomes
can impede the normal function of the cell and give rise
to disease. Indeed, defects in DNA damage responses have
been associated with cancer predisposition, cognitive
decline and premature aging disorders (2–4).
The major repair pathway responsible for handling the
most common forms of DNA damage is base excision
repair (BER) (5). In brief, this process involves the
excision of a base lesion, incision at the resulting AP
site, clean-up of the SSB, gap-filling and sealing of the
remaining nick. A prominent participant in the repair of
DNA SSBs is X-ray cross-complementing 1 (XRCC1), a
non-enzymatic factor that operates as a scaffold protein
during the repair response (6). XRCC1 has biologically
significant interactions with the DNA strand break
sensor poly(ADP-ribose) polymerase 1 (PARP-1), the
gap-filling DNA polymerase b (POLb), the DNA
30-phosphatase (PNKP) and DNA ligase 3a (LIG3a)
(7–11). In addition to its repair functions during the
G(1) cell cycle phase, XRCC1 operates in unique, yet un-
defined ways to facilitate S-phase, replication-associated
repair events (12–16). Defects in XRCC1 are connected
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with increased sensitivity to a number of DNA-damaging
agents [e.g. methylmethane sulfonate (MMS) and ionizing
radiation (IR)], compromised SSB repair (SSBR), and
elevated sister chromatid exchange (6,17).
Deficiencies in human BER have been causally
associated with cancer susceptibility or disease develop-
ment. For instance, mutations in the MutY DNA
glycosylase, MYH, or in the nuclear uracil DNA
glycosylase, UNG, are genetically linked to colorectal
cancer or hyper-IgM syndrome, respectively (18,19).
More indirect correlations of defective BER and disease
risk have been suggested for POLb variants, which are
detected in a high percentage of tumors and exhibit
mutator characteristics (20). In the case of XRCC1, a
large number of single nucleotide polymorphisms (SNPs)
that affect amino acid composition have been reported in
the human population, and epidemiology studies have
found an association of some of these with cancer risk
(21–23). However, little is known about the molecular
repair capacity of the altered XRCC1 proteins, and the
epidemiological association studies have often been incon-
clusive or contradictory. In addition to the human
variants, XRCC1 mutations have been identified in
Chinese hamster ovary (CHO) cell lines that exhibit
increased sensitivity to DNA-damaging agents as well as
genomic instability (24).
To define the repair capacity of XRCC1 amino acid
variants, we purified a select group of proteins and
examined their in vitro interaction capacities with a
number of associating BER protein partners, as well as
with DNA. In addition, following transient transfection
into HeLa cells, we determined the localization and
response dynamics of fluorescent-tagged versions of the
proteins to and from sites of laser-induced DNA
damage. We report herein the results of nine human
XRCC1 variant proteins: V86R and R109A, predicted
by structural analysis to affect POLb and/or DNA
binding (25,26); E98K (&E102K in CHO) and C389Y
(&C390Y in CHO), identified in the repair-deficient
hamster cell lines EM-C12 and EM-C11, respectively
(24); and P161L, R194W, R280H, R399Q and Y576S,
found within the population, and in some instances,
associated with disease susceptibility (21,27). Our data
unveil the molecular defects of XRCC1 in the mutant
EM-C11 and EM-C12 CHO cell lines, and provide novel
insights into the functional consequences of amino acid
substitutions found within the population.
MATERIALS AND METHODS
Creation of site-specific XRCC1 amino acid variant
constructs
The variants R194W and R399Q were created using an
overlapping PCR technique (28). In brief, product 1 (P1),
which was designed to harbor the site-specific mutation
for R194W, was produced by standard PCR amplification
using primers X150Eco and X1Arg194Trp (Table 1), and a
wild-type (WT) XRCC1 cDNA template (14). Unmodified
product 2 (P2) was generated via PCR amplification
using primers X1prod1 and X130Xba (Table 1). For
R399Q, mutation-containing P1 was produced using
X1Arg399Gln and X130Xba, and unmodified P2 was
created with X150Eco and X1prod2 (Table 1). In either
case, P1 was mixed with P2 at a 10:1 ratio, and a third
round of PCR was executed using X150Eco and X130Xba.
This final full-length PCR product was subsequently
digested with EcoRI and XbaI, and subcloned into the
corresponding restriction sites of pcDNA3 (Invitrogen,
Table 1. Oligonucleotides used for the studies herein
Name Oligonucleotide sequence (50–30)
X150Eco CGGAATTCACCATGCCGGAGATCCGCCTCCG
X1Arg194Trp ATGTCTTGTTGATCCAGCTGAAGAAGAG
X1prod1 GCAGCCAGCCCTACAGCAAGGA
X130Xba GCTCTAGATCAGGCTTGCGGCACCACCC
X1Arg399Gln CACCGCATGCGTCAGCGGCTGCCCTCC
X1prod2 CCTCAAAGCTGGGATCCCATT
50X1BlgN GAAGATCTCACCATGCCGGAGATCCGCCTCCG
30XEcoN CGGAATTCGGGCTTGCGGCACCACCCCAT
Variant Primer set and sequence (50–30)
E98K X1E102Kfor: ATG TCC CCT TCC AAG AGC CGC AGT GGC
X1E102Krev: GCC ACT GCG GCT CTT GGAAGG GGA CAT
P161L X1Pro161Leufor: GAG GCA GAG GCC CTG TCC CAG AAG GTG
X1Pro161Leurev: CAC CTT CTG GGA CAG GGC CTC TGC CTC
R280H X1Arg280Hisfor: CCA GCT CCA ACT CAT ACC CCA GCC ACA G
X1Arg280Hisrev: CTG TGG CTG GGG TAT GAG TTG GAG CTG G
C389Y X1C390Yfor: TGG GTG CTG GAC TAT CAC CGC ATG CGT
X1C390Yrev: ACG CAT GCG GTG ATA GTC CAG CAC CCA
Y576S X1Tyr576Serfor: GAG CTC GAG GAC TCT ATG AGT GAC CGG
X1Tyr576Serrev: CCG GTC ACT CAT AGA GTC CTC GAG CTC
Top, oligonucleotides employed for the overlapping PCR mutagenesis or for specific DNA fragment amplication. Bottom,
primer sets used with the QuikChange mutagenesis kit. The amino acid substitution is listed to the left. The forward (for)
and reverse (rev) primer name and its nucleotide sequence are provided in the column to the right. Name and nucleotide
sequence are denoted.
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Carlsbad, CA). Following sequence verification,
mutant-containing inserts were re-amplified and
subcloned into pET29a (Novagen/EMD Chemicals,
Gibbstown, NJ) as described for WT XRCC1 (14).
XRCC1 mutants V86R and R109A, which were
designed previously (9), were transferred from pcDNA3
to pET29a in an identical manner. All plasmid sequences
were confirmed by Lark Technologies (Houston, TX)
prior to use.
Human XRCC1 variants E98K, P161L, R280H, C389Y
and Y576S were created using the QuikChange II
Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
CA). In brief, the forward primer and the reverse primer
(125 ng each; Table 1) were mixed with 10 ng
XRCC1-pET29a plasmid (14), dNTPs, and PfuUltra HF
DNA Polymerase to generate recombinant plasmids har-
boring the desired nucleotide substitution. Plasmids were
then digested by DpnI, which cuts methylated and
hemimethylated DNA, to eliminate WT plasmids (see
manufacturer protocol for details). The remaining, un-
digested plasmids were transformed into XL1-blue cells
(Stratagene), and individual clones were sequence
verified by Lark Technologies.
The WT, yellow fluorescent protein (YFP)-tagged
pXRCC1-EYFP expression construct has been described
previously (14). To create the protein variant constructs,
an XRCC1 cDNA harboring the V86R, E98K, R109A,
P161L, R194W, R280H, C389Y, R399Q or Y576S substi-
tution was PCR amplified from the corresponding
pET29a recombinant plasmid described above using
primers 50X1BLgN and 30XEcoN (Table 1). These
inserts were subsequently digested with BglII and
EcoRI, and subcloned into the identical restriction sites
within pEYFP-N1 (Clontech, Mountain View, CA). All
recombinant plasmids were sequence confirmed by Johns
Hopkins synthesis and sequencing facility (Baltimore,
MD).
Purification of recombinant proteins
pET29a expression plasmids containing an XRCC1
cDNA (WT or variant, see above) were transformed
into Escherichia coli strain BL21 (DE3) (Novagen).
Each protein harbors an N-terminal S-peptide tag and a
C-terminal hexahistidine-tag. Purification of the recom-
binant proteins was performed essentially as described
(14), except protein expression after IPTG induction pro-
ceeded overnight at 20C. Recombinant DNA POLb,
PCNA and PARP-1 were purified as described previously
(29–31).
For the purification of DNA LIG3a, cell cultures of
E. coli strain BL21 (DE3) harboring pGex plasmids ex-
pressing human LIG3a (subcloned into the BamH1 and
SalI restriction sites) with a GST tag at the N-terminus
(32) were grown at 37C to a density of 0.9 at OD600.
Protein induction was initiated by adding IPTG to a
final concentration of 1mM and continued at 9C over-
night. GST-tagged LIG3a was purified using GSTBind
beads (Novagen) according to the manufacturer’s instruc-
tions. Briefly, the pellet from a 150ml cell culture was
suspended in 6ml GST bind/wash buffer (4.3mM
Na2HPO4, 1.47mM KH2PO4, 137mM NaCl, 2.7mM
KCl, pH 7.3). Cells were then lysed by sonication,
followed by centrifugation at 36 000 g for 20min at
4C. The clarified cell extracts were brought to room tem-
perature and loaded onto a column that was packed with
0.5ml GSTBind beads and equilibrated with GST bind/
wash buffer (see details from manufacturer). After the cell
extracts were passed through the column via gravity,
the column was washed with 10ml GST bind/
wash buffer. LIG3a protein was eluted with 1.5ml
GST elution buffer (10mM reduced glutathione in
50mM Tris, pH 8.0) and stored in aliquots at 80C
until needed.
Protein–protein interaction assay
To determine the interaction affinity of XRCC1 for a
specific protein partner, 4 mg of S-peptide-tagged
XRCC1 was incubated with S-protein-agarose
(Novagen) on ice for 1 h with constant mixing. The
matrix was then washed twice with binding buffer
(50mM HEPES–KOH, pH 7.5, 150mM KCl, 0.02mM
EDTA, 1mM DTT, 10% glycerol, 0.015% Triton
X-100) to remove unbound material (14), and an
amount of target protein determined to be within the
linear range of binding capacity (typically around 25%)
was incubated at 4C for 1 h with constant mixing in 50 ml
of binding buffer (1 or 2 mg POLb, 1 mg LIG3a, 3 mg
PCNA and 2 mg PARP-1). The S-protein-agarose was
pelleted by centrifugation, washed four times with 200 ml
binding buffer, and resuspended in SDS–protein gel
loading dye (Bio-Rad, Hercules, CA). Following denatur-
ation at 95C for 10min, the agarose-bound material was
loaded onto a 12% SDS–polyacrylamide gel for electro-
phoresis, and the protein was stained (except for the
PCNA studies, see below) with Sypro Red (Molecular
Probes, Invitrogen). Fluorescence was visualized using a
Typoon Trio+ Variable Model Imager (Amersham
Bioscience/GE Healthcare, Piscataway, NJ), and the
signal was quantified using ImageQuant software as
detailed by the manufacturer (Molecular Dynamics, GE
Healthcare). For the XRCC1-PCNA interaction, western
blotting (WB) was performed to detect bound PCNA
protein. After affinity capture and SDS–polyacrylamide
gel electrophoresis as above, proteins were blotted and
detected with either anti-PCNA (rabbit, Santa Cruz,
CA, Sc-7907) or anti-XRCC1 (rabbit, GeneTex Inc.,
Irvine, CA, RB-XRC10-UP50) antibody. A fluorescence-
labeled secondary antibody (Alexa Flour 488, anti-rabbit,
molecular probes) was used for quantification as above.
To quantify binding activity in each of the cases above,
background binding seen in the control (no XRCC1,
beads only) reaction was first subtracted from the
amount of partner protein detected in the different
XRCC1 reactions, and then the ratio of partner:XRCC1
was determined. The relative binding activity represents
the value obtained by comparing the ratio for the
variant XRCC1 protein reaction to the ratio of the WT
XRCC1 assay (reported as 100) within a given experimen-
tal set.
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In the PARP-1-XRCC1 interaction assays, PARP-1
was ADP-ribosylated (unless otherwise indicated).
ADP-ribosylation was conducted according to ref. (30),
with minor modifications. Eighteen microgram PARP-1
was incubated at 25C for 20min in 45 ml reaction buffer
[100mM Tris, pH 8.0, 100 mM NAD+, 10mM MgCl2,
5mM DTT, 34-mer double-stranded DNA (dsDNA) con-
taining a nick (1 pmol/ml)]. Reactions were then stopped
by the addition of 1.8 ml 0.5M EDTA, and aliquots were
used accordingly to evaluate the interaction affinity of
ADP-ribosylated PARP-1 with the various XRCC1
proteins.
DNA-binding assay
For each set of binding reactions, substrates were
prepared in batch. One-hundred and twenty microliter
of streptavidin gel matrix solution (Pierce/Thermo
Scientific, Rockford, IL) was transferred to a
microcentrifuge tube and pelleted by centrifugation at
4500 g for 1min. The matrix was subsequently
equilibrated in DNA-binding buffer (1PBS, 1%
NP-40) by washing three times and resuspending in
800ml binding buffer. Biotinylated substrate (400 pmol),
either gapped DNA (34Gbio/15BER/pG18) or
double-stranded undamaged DNA (34Gbio/34C) from
Integrated DNA Technology, Coralville, IA or Midland,
Midland, TX, were added and incubated at room tem-
perature for 90min. The streptavadin matrix:biotinylated
DNA complex was pelleted, washed twice with
DNA-binding buffer, and resuspended in 800 ml binding
buffer with BSA (50 mg/ml). Twenty microliter of
streptavadin matrix:biotinylated DNA substrate
(10 pmol) was aliquoted into individual reaction tubes,
and XRCC1 protein (5, 10, 20 or 40 pmol) was added in
a final volume of 30 ml. Reactions were incubated over-
night at 4C with rotation to allow for protein:DNA
complex formation. The streptavadin
matrix:DNA:protein complex was pelleted by centrifuga-
tion at 4500 g for 1min and then washed twice with
DNA-binding buffer. Any stably bound protein was
dissociated from the beads by heating at 95C for 10min
in SDS–protein loading dye and resolved on a 12% SDS–
polyacrylamide gel. Following transfer, WB analysis was
performed using primary antibody against XRCC1
(NeoMarkers/Thermo Scientific, 33-2-5). Signals were
detected using horseradish peroxidase-conjugated second-
ary antibodies and SuperSignal West Femto Maximum
Sensitivity Substrate (Pierce). WBs were captured as
TIFF files and quantitated with ImageQuant TL (GE
Biosciences). Nucleic acid saturation binding curves were
plotted (% substrate bound versus nM XRCC1 concen-
tration) and apparent dissociation constants were
calculated by non-linear curve fitting using the Hill
equation in Origin 7.0 (Northampton, MA). For
DNA-binding reactions with XRCC1 mutant proteins,
20 pmol of each protein was incubated with 10 pmol of
gapped DNA substrate and processed as above. Averages
and standard deviations were calculated from at least trip-
licate experiments and plotted relative to WT XRCC1
binding.
Laser microirradiation and confocal microscopy
We employed a Nikon Eclipse TE2000-E spinning disk
confocal microscope with five laser imaging modules and
a CCD camera (Hamamatsu, Tokyo, Japan). The set-up
integrated a Stanford Research Systems (SRS) NL100
nitrogen laser by Micropoint ablation system (Photonics
Instruments, St. Charles, IL), using a 3 ns pulse width at
10Hz with a diffraction limit spot size of 300 nm. Positions
internal to the nucleus of HeLa cells transfected 24 h pre-
viously with a YFP-tagged XRCC1 construct (see above)
were targeted via a 40 oil objective lens. Transfection
was carried out with the FuGENE 6 Reagent (Roche,
Basel, Switzerland) using 200 000 cells and 1.5mg
plasmid DNA according to the manufacturer’s procedure.
Site-specific DNA damage was induced using the SRS
NL100 nitrogen laser that was passed through a dye cell
to emit at 435 nm wavelength. The power of the laser was
attenuated through Improvison’s Volocity software 4.3.1
(Improvision/PerkinElmer, Coventry, England) in terms
of percent intensity. A laser intensity of 1.5% (total
energy output of 10 nW) was used in all experiments to
create free radical-induced DNA SSBs in the targeted
region; under these parameters, no gH2AX foci, a
marker for double-strand breaks, were observed (data
not shown). Images were captured at various time points
using the same parameters, and the resulting data was
analyzed using Volocity version 4.3.1 build 6
(Improvision). Experiments were performed using an en-
vironmental chamber attached to the microscope to
maintain the normal atmosphere of the cells (i.e. 37C
and 5% CO2).
Fluorescence recovery after photobleaching analysis
Fluorescence recovery after photobleaching (FRAP)
analysis was carried out with live cells transfected with
an YFP tagged XRCC1 plasmid as described above. The
same set up as the microirradiation was used to perform
the photobleaching. Fluorescence recovery was monitored
and the data for recovery was corrected for the back-
ground intensity and loss of total fluorescence.
RESULTS
Integrity of XRCC1 variant proteins
The various site-specific XRCC1 variant proteins
generated for this study were characterized for one of
the following reasons (summarized in Table 2): (i) they
had been previously shown or argued as disruptive of a
specific function and therefore would serve as a control
(V86R, in the POLb interaction; R109A, in the POLb
interaction and/or in DNA binding) (8,9,26); (ii) they
were identified as the principal defect responsible for the
repair-deficiencies associated with the CHO cell lines
EM-C12 and EM-C11 (e.g. E102K and C390Y, respect-
ively, or E98K and C389Y in humans; see protein align-
ment in Supplementary Figure S1) (24); or (iii) they were
found among the normal healthy human population yet
may represent impaired-function, disease susceptibility
factors (P161L, R194W, R280H, R399Q and Y576S;
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Table 3) (27). Since these amino acid substitutions
spanned the length of the XRCC1 protein (Figure 1A),
they might represent separation-of-function mutants de-
fective in only a single (or a limited number of)
interaction(s).
After expression and purification of the various
N-terminal S-peptide-tagged, C-terminal His-tagged, re-
combinant human XRCC1 proteins, experiments moni-
toring whether they exhibited an altered or abnormal
behavior during the process were conducted (see
‘Materials and methods’ section for procedure). For the
most part, each of the XRCC1 variants acted similar to
the WT protein, with V86R and C389Y being the most
visible exceptions (Table 2). V86R showed a slight and
reproducible altered mobility upon resolution in a 12%
SDS–polyacrylamide gel (Tris/glycine-buffered),
migrating somewhat faster than the other full-length re-
combinant XRCC1 fusions (Figure 1B and throughout).
C389Y (associated with the mutant CHO cell line
EM-C11), both in whole cell extracts (not shown) and
following purification via nickel chromatography, was
produced largely as an unstable, truncated (presumably
degraded) product (Figure 1B). Although not as
dramatic as C389Y, the E98K substitution (equivalent to
that seen in EM-C12) appears to destabilize the XRCC1
polypeptide as well, as suggested by the increased degrad-
ation seen in Figure 1B; E98K also exhibited greater sen-
sitivity than the other proteins to multiple freeze-thaw
cycles, as revealed by more rapid degradation (unpub-
lished observation). Other than these deviations, each
protein was expressed to a similar degree and with
similar solubility, and displayed comparable chromato-
graphic properties as WT XRCC1 (summarized in
Table 2). Such data suggest that the particular amino
acid change introduced (other than primarily V86R,
E98K or C389Y) had little or no major effect on the
global structural integrity or general stability of the
XRCC1 polypeptide. Additional experimentation was
not performed with the C389Y preparation.
To further interrogate the state of the various XRCC1
recombinant proteins, their capacity and efficiency to bind
the S-protein affinity matrix was explored. This strategy
Table 2. XRCC1 variant proteins studied here
Variant Background Expression efficiency Purification characteristics
V86R Impaired POLb interaction, control protein Normal Normal; slightly faster
electrophoretic mobility
E98K Associated with EM-C12 mutant cell line,
E102K in CHO; putative DNA-binding mutant
Normal, increased degradation
or instability
Normal
R109A Putative POLb and DNA-binding mutant Normal Normal
P161L Population variant Normal Normal
R194W Population variant associated with disease
susceptibility
Normal Normal
R280H Population variant associated with disease
susceptibility
Normal Normal
C389Y Associated with EM-C11 mutant cell line,
C390Y in CHO
Predominantly a protein
fragment
See ‘Expression efficiency’
R399Q Population variant associated with disease
susceptibility
Normal Normal
Y576S Population variant Normal Normal
Amino acid change is indicated to left. ‘Background’ column reveals origin of substitution. Normal= similar to WT protein, with at most a modest
deviation. See text for further details.
Table 3. Predicted effects of site-specific XRCC1 amino acid substitutions
Variant SIFT prediction (Score) SS element Solvent
accessibility (%)
Tortion angles
(j, c)
Overall stability Tortion Predicted G
(kcal/mol)
V86R Affect protein function (0.04) Sheet 52.70 58.7, 89.4 Destabilizing Unfavorable 0.9
E98K Affect protein function (0) Helix 19.46 65.3, 24.5 Destabilizing Favorable 3.01
R109A Affect protein function (0) Sheet 56.77 131.9, 173.8 Destabilizing Unfavorable 0.4
P161L Tolerated (0.11) – – – – – –
R194W Tolerated (0.12) – – – – – –
R280H Tolerated (0.13) – – – – – –
C389Y Affect protein function (0) Helix 0.00 60.8, 49.5 Destabilizing Favorable 30.7
R399Q Tolerated (0.19) Helix 81.22 67.7, 21.7 Destabilizing Favorable 6.08
Y576S Affect protein function (0) Other 58.49 168.3, 146.5 Stabilizing Favorable 0.64
Sorting intolerant from tolerant (SIFT) uses sequence homology to predict whether an amino acid substitution will affect protein function
(http://blocks.fhcrc.org/sift/SIFT.html). The score is the normalized probability that the amino acid change is tolerated; SIFT predicts substitutions
with scores <0.05 as deleterious. CUPSAT is a method based on three-dimensional structural parameters (http://cupsat.tu-bs.de/). This prediction
model uses amino acid-atom potentials and torsion angle distribution to assess the amino acid environment of the mutation site. CUPSAT can also
distinguish the amino acid environment using its solvent accessibility and secondary-structure specificity. ‘–’ indicates not applicable, as no structure
information exits. See Figure 7 legend for further details.
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was not only an additional means of assessing the integrity
of the variant proteins, but also a method to determine
sample purity prior to use in the affinity capture (inter-
action) studies described below. Following binding to the
S-protein agarose column, recombinant XRCC1 proteins
were eluted, separated on a 12% SDS–polyacrylamide gel,
and silver stained. As shown in Figure 1C, all proteins
behaved similar to WT (recognizing the exceptions
above) and were purified to >95%. The fact that each
protein (excluding C389Y) binds to both the nickel and
S-protein affinity column indicates that each retains the
C- and N-terminal hexahistidine and S-peptide tags,
respectively, and therefore is full-length. This observation
suggests that the apparent slightly altered electrophoretic
mobility of recombinant V86R arises from a unique
physical or chemical feature induced by the amino acid
change, and not an N- or C-terminal truncation.
Interaction affinities of XRCC1 proteins
We examined the interaction stability of the various
XRCC1 variants with several major associating protein
partners (Figure 1A). Towards this end, a previously
devised affinity capture strategy was employed (14). This
approach involved binding of the S-peptide-tag recombin-
ant fusion proteins to the S-protein agarose matrix
(Figure 1C), and subsequently incubating this complex
with a protein of interest. After permitting the protein–
protein interaction to occur (at a concentration of protein
determined to be within the linear range of binding; see for
instance, Figure 2A), bound material was captured,
separated on a denaturing SDS–polyacrylamide gel, and
either stained with Sypro Red or visualized via WB
analysis using fluorescence-labeled secondary antibody.
Both approaches permitted reliable quantification of the
signal intensity of the relevant bands (see ‘Materials and
Methods’ section). The amount of retained target protein
relative to XRCC1 was plotted against the value obtained
for WT (arbitrarily set at 100), with reduced retention
indicating impaired interaction stability.
Initial studies examined the effect of the various amino
acid substitutions on the association of XRCC1 with
DNA POLb (Figure 2). As anticipated, the most
dramatic effect was observed with the V86R mutant,
where POLb retention was equivalent to (or less than)
the POLb alone (beads only) negative control in three in-
dependent experimental runs (Figure 2B and C). This is in
line with prior biochemical experiments using the
N-terminal domain (NTD) of XRCC1 (26) and with
yeast two-hybrid analysis using the full-length protein
(8), where both studies indicated that a V to R substitution
at position 86 profoundly destabilized the POLb inter-
action, validating the experimental in vitro approach. In
addition, we observed a reproducible and significant
5-fold (83%) decrease in POLb retention with the
R109A variant (Figure 2B and C), a finding also consist-
ent with prior biochemical studies using an N-terminal
Figure 1. Relevant amino acid positions and regions of human XRCC1, and purification of XRCC1 proteins. (A) Linear schematic of the XRCC1
protein. Indicated are the four major conserved elements of XRCC1: the N-terminal domain (NTD), the nuclear localization signals (NLS), the
BRCT1 and the BRCT2 domains. Numbers represent the amino acid positions within the XRCC1 polypeptide. The locations of the amino acid
substitutions are indicated above the diagram. The regions of XRCC1 that interact with specified protein partners are denoted. (B) Nickel column
affinity purified XRCC1 proteins. C-terminal His-tagged, N-terminal S-peptide-tagged XRCC1 recombinant proteins expressed in bacteria were
purified using nickel chromatography. Shown is an image of the purified proteins separated in a 12% SDS–polyacrylamide gel and stained with
coomassie blue. (C) Nickel and S-protein affinity purified XRCC1 proteins. Following nickel purification, dual-tagged XRCC1 recombinant proteins
were affinity captured using an S-protein matrix. Shown is an image of silver stained purified proteins after separation in a 12% SDS–polyacrylamide
gel. Arrows indicate XRCC1. STD=protein standards (in kDa).
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XRCC1 fragment containing a R109S substitution (26).
No defect (i.e. <20%) in the POLb interaction was seen
for the XRCC1 variants R194W, R280H and R399Q,
whereas a marginal defect (20–30%) was observed for
Y576S, as well as with E98K and P161L (Figure 2B
and C), the latter two of which harbor an amino acid
change within or near the POLb interaction domain
(Figure 1A).
As the above experiments with DNA POLb validated
the use of the affinity capture technique to assess rela-
tive binding affinity [see for instance, ref. (26)], similar
interaction studies using the purified protein partners
PARP-1, LIG3a and PCNA, which span the various
functional regions of the XRCC1 polypeptide, were per-
formed (Figure 1A). As shown in Figure 3A,
ADP-ribosylated PARP-1 interacted with all of the
XRCC1 variant proteins with similar affinity as WT. We
note that ADP-ribosylation of PARP-1 enhanced the
interaction with WT XRCC1 (Supplementary Figure S2),
as described previously (7,33). As with PARP-1, no inter-
action deficiency for any of the XRCC1 variants was
observed with DNA LIG3a (Figure 3B). Given that
the association of XRCC1 with PCNA appears 5-fold
weaker than its association with the other proteins
examined herein, we used WB analysis to improve the
detection of captured PCNA. These studies revealed
that none of the variant XRCC1 proteins exhibited a
statistically significant defect in their affinity for PCNA
(Figure 3C).
DNA-binding activities of XRCC1 proteins
Besides the specific protein–protein interactions outlined
in Figure 1A, XRCC1 has also been reported to exhibit
nick- or gap-preferred DNA-binding activity (25,34). In
addition, the BRCT2 domain of XRCC1 has
been shown to associate with DNA double-strand break
ends (35). Studies were designed to determine the
impact of the various site-specific mutations on DNA
binding. Towards this end, an affinity matrix
DNA-binding assay was developed. In brief,
Figure 2. Interaction of XRCC1 with DNA POLb. (A) Titration of
XRCC1–POLb interaction. XRCC1 (4 mg) was bound to S-protein
agarose, mixed with POLb (0.1, 0.3, 1 or 3 mg), and the two proteins
captured as described in ‘Materials and Methods’ section. Bound
proteins were separated in a 12% SDS–polyacrylamide gel and
stained with Sypro Red (inset). The resulting signal ratio of POLb/
XRCC1 (y-axis) is plotted against the initial POLb amount (x-axis).
(B) A representative gel image of an XRCC1–POLb affinity capture
experiment. Experiment was carried out with the indicated XRCC1
protein (4 mg) and POLb (2 mg). The intensity of the minor (back-
ground) POLb band seen in the V86R lane was similar to the
negative control reaction without XRCC1 (i.e. POLb alone, Cntrl).
(C) Relative interaction affinity of XRCC1 proteins for POLb.
Shown is the average and standard deviation of three independent ex-
perimental runs. Values represent the POLb:XRCC1 signal ratio, with
WT being arbitrarily set at 100. Standard deviation of the values for
the WT-binding reactions is shown as well.
Figure 3. Relative affinities of XRCC1 proteins for PARP-1 (A),
LIG3a (B) and PCNA (C). Shown are the average and standard devi-
ation of three independent affinity capture experiments. See Figure 2, as
well as text, for further details. Values represent the resulting signal
ratio, with WT being arbitrarily set to 100. Standard deviation of the
values for the WT-binding reactions is shown as well.
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single-stranded 34-mer 50-biotin-tagged oligonucleotide
(34Gbio) and complementary oligonucleotides (34C, 34F
or 15BER/pG18) were annealed to create unmodified
(dsDNA) or damage-containing (either AP-DNA or
Gap DNA) substrate molecules (Supplementary Figure
S3A). These DNA molecules were affixed to streptavidin
agarose beads and subsequently incubated with the
protein of interest (see below) to permit complex
assembly, washed to remove unbound or weakly
bound material, and then analyzed by WB to reveal the
presence of stably bound protein. The more stable
the interaction, the more protein that will be retained on
the DNA matrix.
To establish the utility of this approach, Ape1 binding
to unmodified duplex DNA and duplex DNA containing
an AP site (AP-DNA) at various substrate concentrations
was examined. We anticipated that more Ape1 protein
would be associated with AP-DNA than with unmodified
duplex DNA, based on previously-determined affinities
(36). As shown in Supplementary Figure S3B (upper
panel), a significant difference between the signal for the
AP duplex and the normal duplex (4-fold) when 20 pmol
DNA and 2.8 pmol Ape1 were used. An additional means
of method validation, DNA POLb, the major gap-filling
DNA polymerase in mammals, was also employed (37).
As shown in Supplementary Figure S3B (lower panel), at
each concentration of DNA tested, POLb exhibited a
more stable interaction with the 1-nt gap substrate
relative to the unmodified dsDNA control, consistent
with the reported data (38) and similar to what was
anticipated for XRCC1 (see below). These studies
indicate that such a binding approach can be employed
to reveal DNA-binding preferences, at least semi-
quantitatively.
Using parameters established above and dsDNA and
Gap DNA (Supplementary Figure S3A), the comparative
binding affinities of WT XRCC1 were determined.
Such analysis indicated that under the conditions used
herein, XRCC1 binds the two 34-mer oligonucleotide sub-
strates with similar affinities (apparent KD values of
600 nM) (Figure 4A and B). Since previous studies
have indicated a higher affinity for nick and gapped
DNA substrates relative to intact duplex DNAs (25,34),
the utility of the assay was re-evaluated by examining
binding of the NTD of XRCC1 (XRCC1NTD) to
dsDNA and Gap DNA. Consistent with the previous
reports, XRCC1NTD preferentially bound to Gap DNA
relative to dsDNA, with 2-fold preference in these
assay conditions (Supplementary Figure S3C).
Finally, the DNA-binding affinities of the variant
XRCC1 proteins for Gap DNA were compared. These
studies revealed that V86R (1.5-fold), E98K (1.7-fold),
R109A (1.5-fold) and R194W (1.5-fold) displayed
slightly enhanced affinities for the Gap DNA duplex sub-
strate in comparison to WT XRCC1 (Figure 4C).
Interestingly, the R280H mutant displayed a decreased
affinity for Gap DNA binding relative to WT. None of
the other variants exhibited a quantitative difference in
DNA-binding affinity for dsDNA containing a 1-nt gap
(Figure 4C).
Intracellular localization and distribution dynamics of
XRCC1 proteins
YFP-tagged XRCC1 expression constructs, for each of the
variants outlined in Table 2, were created to determine
protein localization and functional capacity in human
cells. Specifically, the intracellular localization and the
damage-induced redistribution kinetics of each XRCC1
protein after transient transfection into HeLa cells were
evaluated. As shown in Figure 5, under normal cell culture
conditions, other than mutant E98K, each of the XRCC1
variants appeared similar to WT in that the protein
resided largely in the nucleoplasm, exhibiting in some in-
stances a punctated foci pattern that was found previously
to reflect S-phase cells and active replication factories (e.g.
see WT, inset) (14), and was excluded from the nucleolus.
C389Y, although showing a sub-cellular distribution
similar to WT, exhibited a reduced fluorescent signal in-
tensity in many of the cells (Figure 5, solid arrow heads),
likely indicative of the protein instability observed in
bacteria (Figure 1). As for E98K, this mutant displayed
an irregular distribution pattern in which the protein was
Figure 4. Binding of XRCC1 to DNA. (A) Representative WB blot.
Indicated substrates (10 pmol) were captured on streptavidin beads and
incubated with XRCC1 (5, 10, 20 or 40 pmol), and bound protein was
pulled down and detected by WB. (B) Graph displaying full-length
XRCC1 binding to unmodified duplex or single nucleotide gapped
DNA substrates. Shown is the average and standard deviation of
three independent experimental runs. (C) DNA-binding activities of
the XRCC1 variants. Shown is a graph of the binding to Gap DNA
of various XRCC1 mutant proteins compared to WT. Standard devi-
ation of the values for the WT XRCC1 binding reactions is shown as
well.
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sequestered primarily in the nucleolus in most cells
(Figure 5, arrows), although in some instances, the
mutant exhibited sharp punctated staining in the nucleo-
plasm (Figure 5, open arrow head).
Since XRCC1 interacts with several protein partners
during the response to DNA SSBs (6), we reasoned that
examination of the relocalization kinetics of the XRCC1
variants would uncover any deleterious effect of a particu-
lar amino acid substitution on protein coordination events
that take place in vivo. Specifically, the redistribution
dynamics of the XRCC1 variants to/from site-specifically,
laser-induced DNA damage under parameters that
generated DNA single-, but not double-strand breaks,
were determined (see ‘Materials and methods’ section).
For relocalization to the sites of DNA damage, each of
the variant proteins displayed WT kinetics, appearing at
the laser-targeted region 10–15 s (Supplementary Figure
S4), except for E98K, which never formed observable
stripes (data not shown), presumably due to its
abnormal localization pattern (Figure 5), and C389Y,
which also never formed detectable stripes (Figure 6A),
likely due to its reduced protein stability and possibly as
a consequence of a defective interaction with PARP-1 (see
site of substitution in Figure 1A).
Disappearance of the YFP-XRCC1 signal was also
monitored from the site of laser-induced DNA SSBs. As
shown in Supplementary Figure S5, each of the XRCC1
variants displayed retention kinetics similar to WT, with
stripe dissolution occurring from 45min to 1 h after
damage induction; E98K and C389Y were not
evaluated in these experiments as they did not localize
to the site of DNA damage (see above). The lone
exception to this result was the R280H polymorphic
variant, which exhibited slightly reduced retention
kinetics, disappearing 15–30min post-microirradiation
(Figure 6B).
DISCUSSION
XRCC1 is a non-enzymatic scaffold protein thought to
coordinate and facilitate efficient SSBR through its
numerous protein-protein interactions (6). Complete
absence of XRCC1 in mice leads to embryonic lethality,
and a deficiency in this protein in mammalian cells results
in chromosome instability and increased DNA-damaging
agent sensitivity (39–42). Furthermore, XRCC1 has been
linked to proteins found to be defective in inherited
spinocerebellar ataxias, e.g. TDP1 and Aprataxin, sug-
gesting a connection between SSBR efficiency and
neuronal cell survival (43,44). Given this information, it
seems reasonable to hypothesize that individuals with
impaired XRCC1 function would exhibit elevated risk of
disease manifestation. These studies were aimed to define
the functional capacities of XRCC1 variants found in
repair-deficient CHO cell lines as well as in the human
population (Tables 2 and 3).
The structure-based V86R mutation completely
disrupts the interaction of XRCC1 with DNA POLb
in vitro [consistent with previous findings (8,26)], but this
substitution does not affect binding to PCNA, PARP-1, or
LIG3a. Molecular modeling of the V86R mutation reveals
a significant change in the electrostatic charge of the NTD
of XRCC1, whereby the largely negatively charged inter-
face of the WT protein becomes mainly positive in the
mutant (Figure 7A). This change in electrostatic surface
charge likely is the reason for the decreased POLb
binding. Given the findings within, V86R appears to rep-
resent a true, separation-of-function mutant. Studies
demonstrating the inability of V86R to complement the
repair-deficiencies of xrcc1 mutant CHO cell lines (8,9)
highlight the importance of the XRCC1–POLb interaction
in mediating a proficient DNA damage response.
However, the localization studies in HeLa cells indicate
that interaction between these two proteins is not critical
Figure 5. Intracellular distribution of XRCC1 variants. The indicated XRCC1 YFP-tagged fusion protein constructs were transiently transfected
into HeLa cells, and fluorescent protein visualized by 491 nm GFP laser. The inset highlights a WT expressing cell with punctated nuclear staining.
The arrows indicate cells where E98K is concentrated in the nucleolus, while the open arrow head denotes a cell with broad nuclear staining and
strong punctated foci. The closed arrow heads point out cells that express C389Y at low levels.
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for targeting XRCC1 to laser-induced DNA damage,
which is presumably comprised of primarily free
radical-generated SSBs. This protein–protein interaction
may instead be required to facilitate POLb gap-filling
polymerization activity (45) and/or coordinate efficient
nick ligation (46), although normal disassembly of
V86R XRCC1 stripes from sites of introduced DNA
damage was seen.
In vitro studies revealed that the structure/
function-based R109A substitution results in a 80%
reduced binding affinity of XRCC1 for full-length DNA
POLb. This observation is consistent with the prediction
that R109 mediates interactions with POLb (Figure 7A)
and with biochemical data indicating that an R109S sub-
stitution in the NTD of XRCC1 reduces (by 30-fold)
binding affinity for the 22 kDa interaction domain of
POLb (25,26). Interestingly, the R109A mutant displayed
normal DNA-binding activity, arguing against a promin-
ent role for this residue in directing protein–DNA inter-
actions as suggested previously. In line with the results of
V86R, normal relocalization kinetics for the R109A
mutant in the laser-induced DNA damage response
studies were observed, supporting the conclusion that
the physical association of XRCC1 with POLb is not es-
sential for effective targeting of the former protein to sites
of DNA damage.
The XRCC1 mutants C389Y and E98K, which are
responsible for the repair deficiencies of the EM-C11
and EM-C12 CHO cell lines, respectively, were found to
exhibit varying degrees of expression efficiency/stability
when produced in bacteria. In the case of C389Y, little
to no full-length protein was detected in bacterial cell
lysates or following nickel-column chromatography. This
impaired protein production/stability is consistent with
the absence of C389Y in EM-C11 cell extracts as
determined by WB analysis (24), and suggests that the
CHO EM-C11 mutant line is for all extensive purposes
XRCC1 null. Amino acid position 389 is buried within
the XRCC1 protein structure and is predicted to have
no solvent accessibility, and both sorting intolerant from
tolerant (SIFT) and Cologne university protein stability
analysis tool (CUPSAT) calculate that a C389Y
mutation would destabilize or adversely affect protein
function (Table 3). That said, WT expression of C389Y
was observed in a subset of HeLa cells. In situations where
C389Y was detectable, the mutant protein was not
targeted to sites of laser-induced DNA damage. Since
this residue is positioned within the PARP-1 interaction
domain, it is possible that this amino acid change nega-
tively affects this protein–protein association, resulting
in impaired recruitment of XRCC1 to sites of lesion pro-
cessing. Indeed, prior studies have demonstrated that
XRCC1 targeting and function is dependent on
poly(ADP-ribosyl)ation and PARP-1 at DNA SSBs
(47–49).
Figure 6. Relocalization of XRCC1 proteins to and from sites of laser-induced DNA damage. (A) Redistribution kinetics of WT and the XRCC1
C389Y variant. Shown are still images taken at the indicated time point (in seconds) after prebleach. The box denotes the region of laser-induced
DNA damage, while the arrow indicates the first point and location at which clear ‘stripe’ formation is observed. (B) Retention kinetics of WT and
R280H XRCC1 proteins. After laser-induced DNA damage induction, peak stripe was observed at 5min. Shown is the loss of signal at 15, 30 and
45min post-irradiation. Each protein (denoted) was analyzed five times and the data presented are mean intensity values obtained in a given
experiment following of substraction of the prebleach background.
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In the case of E98K, the recombinant protein exhibited
only a slight decrease in overall stability when expressed in
bacteria as revealed by increased degradation (although
the protein did show hypersensitivity to freeze-thaw
events). This is in apparent contrast to the observation
that E98K is absent from EM-C12 cell extracts (24), but
may reflect differences in expression conditions and/or
cellular environments, variation in half-life stability, limi-
tations in WB detection, or stabilization by the affinity or
visualization tags. Nonetheless, the biochemical data
herein suggest that the cellular defects associated with
EM-C12 are likely the cumulative result of (i) reduced
XRCC1 protein levels (24), (ii) a slightly impaired inter-
action with DNA POLb and (iii) a slightly enhanced
DNA-binding affinity, a feature that is consistent with
the previous proposal that mutation of E98 to a positively
charged residue such as K might enhance DNA-binding
affinity (25). Molecular modeling of the electrostatic
surface of E98K predicted an increase in positive charge
compared to WT XRCC1 (Figure 7A), a change that
likely affects interactions with both POLb and DNA.
Finally, the studies performed in HeLa cells revealed an
unusual localization pattern for E98K, where the protein
was found primarily sequestered in the nucleolus. In fact,
the laser-mediated redistribution experiments did not
detect relocalization of E98K to the sites of DNA
damage (data not shown), presumably the result of
abnormal XRCC1 intracellular targeting.
Our data indicate that full-length XRCC1 exhibits
similar DNA-binding activity for unmodified duplex
DNA and duplex DNA containing a single nucleotide
gap. Previous studies, however, have found that XRCC1
displays a higher affinity for DNA containing a nick
(7–8-fold) or a one nucleotide gap (3–4-fold) than for
intact ds or ssDNA (34). Since we demonstrated that
XRCC1NTD exhibits increased binding activity for Gap
DNA relative to dsDNA (Supplementary Figure S3C),
our results suggest that additional portions of XRCC1
likely contribute to DNA binding, such as the BRCT2
domain (35). Supportive of this, slightly enhanced Gap
DNA binding for the R194W variant and decreased
binding for R280H, residues that fall outside of the
NTD of XRCC1, was observed (Figure 1A). It seems
worthwhile to more thoroughly define the molecular
nature of the XRCC1–DNA interaction(s), as well as the
contributions of the various protein domains to substrate
recognition/discrimination.
Neither of the rare variants, P161L or Y576S (found at
frequencies of 1% in the human population), were found
in vitro to exhibit major defects in their interaction
affinities with POLb, PCNA, PARP-1, LIG3a or DNA.
While there was some indication that P161L may display a
Figure 7. Molecular modeling of XRCC1 and site-specific mutants. XRCC1 N-terminus (PDB ID: 1XNA), BRCT1 (PDB ID: 2D8M) and BRCT2
(PDB ID: 1CDZ) domains were downloaded from PDB (http://www.rcsb.org/pdb). Variant structure models were generated using SWISS-MODEL
(http://swissmodel.expasy.org//SWISS-MODEL.html). Electrostatic surface charge calculations were generated by creating PQR files using
PDB2PQR (http://pdb2pqr.sourceforge.net/), and subsequently the biomolecular solvation was modeled through solution of the Poisson-Boltzman
equation by APBS (http://apbs.sourceforge.net/) and visualized using PyMol (DeLano Scientific). (A) WT XRCC1 NTD displaying POLb interacting
amino acids (magenta) and positions of disruptive amino acid mutants (yellow) boxed in white (left panel). Electrostatic surface charge models of
XRCC1 N-terminus for WT, V86R and E98K. White boxes denote amino acid position 86 or 98, as essentially arranged in panel to left, and the
immediately surrounding amino acids. (B) WT XRCC1 C-terminal BRCT domain displaying Ligase III interacting amino acids (magenta) and
position of non-disruptive amino acid position 576 (yellow) boxed in white (left panel). Electrostatic surface charge models of XRCC1 C-terminal
BRCT domain WT and Y576S. White boxes denote amino acid position 576 and immediately surrounding amino acids.
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marginal defect in its interaction with POLb, this 20%
deficiency likely reflects limitations in the assay, as a
similar defect was seen for Y576S, a mutation some
distance from the POLb interacting region (Figure 1A).
The lack of an interaction defect between Y576S and
DNA LIG3a is consistent with (i) this amino acid
residue location in XRCC1 is somewhat distant from the
precise protein-protein interface (Figure 7B) and (ii) a
mutation that does not dramatically affect surface electro-
static charge (Figure 7B) or protein structural integrity as
assessed by CUPSAT (Table 3). Since P161L and Y576S
are similar in function to the WT protein, including in
their cellular localization patterns, it is unlikely that
either is a susceptibility or disease allele.
As for the high frequency (polymorphic) variants,
R194W and R399Q, no major interaction deficiency was
observed for the primary protein partners POLb, PCNA,
PARP-1 and LIG3a, or for DNA. Moreover, these
variants, as well as R280H, exhibited normal intracellular
distribution patterns when expressed in HeLa cells,
indicating no impairment, for instance, of the putative
nuclear localization signal. While several reports have
described an association of R194W or R399Q with
disease susceptibility (21,50,51), there are nearly as many
studies that have failed to see a risk association for these
variants. Since none of the studies herein indicate that
R194W and R399Q XRCC1 proteins are functionally de-
fective, it seems unlikely that they are responsible for the
investigated disease development. As for R280H, this
variant displayed a shortened retention time at sites of
laser-induced DNA SSBs, as well as a slight defect in
DNA binding in vitro. Such results are seemingly consist-
ent with past complementation experiments, in which two
out of three studies have found that R280H exhibits an
impaired biological function (52–54). Moreover, a few in-
vestigations have found that the R280H variant of
XRCC1, in contrast to variants R194W or R399Q,
imparts a reduced DNA repair capacity phenotype as
assessed by the Comet assay (55,56). Thus, although
there are mixed reports on R280H, our data supports
the evidence that the R280H genotype is more likely a
negative risk factor than R194W and R399Q in disease
susceptibility, possibly due to a defect in DNA binding.
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